Blood Cancer Talks
This podcast focuses exclusively on the management of blood cancers and hematology. The twice-monthly episodes are hosted by Rajshekhar Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD.
Advertisement
Alexander Perl, MD, joins the hosts to discuss the management of newly diagnosed and relapsed FLT3-positive AML.
The episode also discusses Dr. Raza's book, "The First Cell," which recounts stories of her patients with terminal cancer.
Kate Cwynarski, MBBS, PhD, of the University of College London, discusses the management of CNS lymphomas.
This episode of "Blood Cancer Talks" discusses the biology and management of multiple myeloma and the role of venetoclax.
The episode also highlights the S1211 study, which is the first randomized controlled trial with high-risk enrichment in MM.
Dr. Horwitz and the hosts focus on the three most common types of PTCL and the latest research.
Advertisement
Uma Borate, MBBS, joins the hosts to discuss CCUS and the latest data.
Dr. Brodsky and the hosts discuss treatment options for PNH and key recent research on the subject.
Dr. Bartlett and the hosts explore the history of first-line treatments for patients with Hodgkin lymphoma.
Dr. Jain discusses how he addresses the acute toxicities that can arise after CAR T-cell therapy.
The hosts discuss the latest data on CAR-T from the summer conference season.
Dr. Sekeres also speaks about his time on the FDA ODAC and his latest book, titled "Drugs and the FDA."
Dr. Chari and the hosts also discuss a phase I trial of fixed-duration cevostamab, as well as a phase I trial of ABBV-383.
Dr. Dreyling discusses the management of newly diagnosed MCL and considerations in light of the TRIANGLE trial.
The episode was inspired by an article titled “The Underrepresented Majority" by Andrés Gómez-De León, MD.
Dr. Tefferi discusses risk stratification systems for primary myelofibrosis, transplant considerations, and more.
Dr. Gertz and the hosts provide an overview of risk-stratification approaches and clinical trials in smoldering MM.
Dr. DeZern discusses the latest research in the management of acquired aplastic anemia.
Dr. Patel and the hosts discuss the phase III ASAP and Dauno-Double trials, menin inhibitors, and more.
This episode provides listeners with DLBCL management strategies and an overview of the latest research in the field.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.